Development of a novel somatostatin analogue G02113 for the treatment of acromegaly and neuroendocrine tumours

• Research unit: INNOSUISSE
• Project number: 15808.1 PFLS-LS

Short description (German)

Development of a novel somatostatin analogue G02113 for the treatment of acromegaly and neuroendocrine tumours

Short description (English)

Development of a novel somatostatin analogue G02113 for the treatment of acromegaly and neuroendocrine tumours

Abstract (German)

The aim of this project is to complete key early developmental experiments for an anti-tumour peptide analogue therapy for patients with rare neuroendocrine tumours or acromegaly resistant, or poorly controlled, with available somatostatin analogues. The peptide analogue has high affinity for the two most important somatostatin receptors in growth hormone control, SSTR2 and 5. This novel tandem therapy will provide enhanced life expectancy, better clinical control and improved quality-of-life to the population of uncontrolled patients.

Abstract (English)

The aim of this project is to complete key early developmental experiments for an anti-tumour peptide analogue therapy for patients with rare neuroendocrine tumours or acromegaly resistant, or poorly controlled, with available somatostatin analogues. The peptide analogue has high affinity for the two most important somatostatin receptors in growth hormone control, SSTR2 and 5. This novel tandem therapy will provide enhanced life expectancy, better clinical control and improved quality-of-life to the population of uncontrolled patients.